Abstract P125 Table 1

	No prior LABD treatment						Prior LABD treatment

	All

T+O		T			T+O				T

Baseline characteristics
n	426		454			603				579
Age (years), mean ± SD	62.7 ± 8.3		62.6 ± 8.8			64.6 ± 8.3				64.8 ± 8.2
Male, n (%)	291 (68.3)		338 (74.4)			442 (73.3)				417 (72.0)
Ex-smoker, n (%)	241 (56.6)		278 (61.2)			388 (64.3)				385 (66.5)
Post-bronchodilator FEV₁ (L), mean ± SD	1.38 ± 0.52		1.43 ± 0.54			1.32 (0.50)				1.32 (0.51)
Post-bronchodilator FEV₁ (% predicted), mean ± SD	50.7 ± 16.0		50.8 ± 15.7			48.3 ± 14.7				48.8 ± 15.6
Reversibility (mL), mean ± SD	158 ± 160		166 ± 144			169 ± 138				174 ± 147
Lung function after 24 weeks of treatment
Adjusted mean FEV₁ AUC_0–3,(mL) ± SE	270 ± 1		154 ± 9			256 ± 8				150 ± 8
Adjusted mean trough FEV₁(mL) ± SE	148 ± 1		72 ± 1			134 ± 8				86 ± 8
	GOLD 2
	T+O	T		T+O				T
Baseline characteristics
n	228	240		274				277
Age (years), mean ± SD	63.0 ± 8.2	62.5 ± 8.9		65.3 ± 8.9				64.8 ± 8.7
Male, n (%)	148 (64.9)	160 (66.7)		202 (73.7)				180 (65.0)
Ex-smoker, n (%)	117 (51.3)	128 (53.3)		176 (64.2)				179 (64.6)
Post-bronchodilator FEV₁ (L), mean ± SD	1.72 ± 0.44	1.77 (0.47)		1.69 (0.44)				1.69 (0.45)
Post-bronchodilator FEV₁ (% predicted), mean ± SD	63.2 ± 8.8	63.1 ± 8.4		62.0 ± 7.4				62.7 ± 8.1
Reversibility (mL), mean ± SD	175 ± 156	184 ± 163		201 ± 151				196 ± 170
Lung function after 24 weeks of treatment
Adjusted mean FEV₁ AUC_0–3,(mL) ± SE	289 ± 13	175 ± 13		302 ± (12)				179 ± 12
Adjusted mean trough FEV₁(mL) ± SE	146 ± 14	68 ± 14		156 ± 13				95 ± 13